

FACTS AND FIGURES

Bio 1-Quickset injectable self-hardening resorbable bone void filler: Injectability, setting time, and compressive strength

S. Moisenier, M.Sc.¹

Introduction

Calcium phosphate ceramics are now well accepted as bone void fillers. Such calcium phosphates can also be used as a cement, so called CPCs (calcium phosphate cements). The primary advantage of injectable bone void filler over blocks, granules, or powders is the ability to custom-fill defects. Capable of hardening in situ, calcium phosphate cements can be injected or molded during surgery, and will lead to a complete filling of a defect, independent of size or shape, improving bone–implant contact ⁽¹⁾. Irregular bone defects can so be completely filled. It also allows for a minimally invasive approach of defect that are accessible under radioscopic control.

Injection of a resorbable bone void filler into an osseous defect may help to stabilize the fracture and to maintain osseous integrity as the substitute is resorbed and replaced by bone ⁽²⁾.



Figure 1: SBM Bio 1-Quickset injectable filler

The ability of calcium phosphate bone substitutes to act as a bone void filler has been documented in animal studies and human case series ^{(3) (4)}.

These bony voids may be created surgically or result from traumatic injury. Clinical applications include:

Treatment of primary metaphyseal bone defects and extremities (**with osteosynthesis**):

- distal radius fractures ^{(5) (6) (7) (8) (9)}
- calcaneus fractures ^{(10) (11) (12) (13)}
- proximal and distal tibia fractures ⁽¹³⁾
- fibula fractures ⁽¹³⁾
- proximal and distal femur fractures ⁽¹³⁾
- proximal humerus fractures ^{(13) (14)}
- phalanx and metacarpals fractures ⁽¹³⁾
- acetabulum fractures ⁽¹³⁾
- tibial plateau fractures ^{(15) (16) (17)}
- hip fractures ^{(18) (19)}
- unstable trochanteric fractures ^{(20) (21)}
- femoral neck fractures ^{(22) (23)}
- acetabular reconstruction

Filling of bone cavities :

- removing benign cysts and tumors ⁽²⁴⁾, including fibrous dysplasia, enchondroma and bone tuberculosis ⁽¹³⁾
- iliac crest bone harvesting sites ⁽¹³⁾
- post-traumatic bone defects ⁽²⁵⁾
- periodontal intraosseous defects ^{(26) (27) (28) (29)}

Injectable bone substitutes that set in situ are also suitable for screw fixation in low quality bone with a high risk of loosening ^{(30) (18) (31) (32) (33)}.

Material and Methods

Development of injectable bone void filler implies both chemical and physical characterisation of the three main phases of the material:

- the components, i.e. the powders, liquids and eventual additives
- the injection time and the setting time of the paste into a solid material
- the properties of the end product.

During setting, a dissolution and precipitation reaction occurs in presence of a liquid, leading to the formation of calcium phosphate and sulfate crystals.

Material

Bio 1-Quickset is a self-hardening resorbable bone void filler that is injectable and biocompatible. It is made of pure beta tricalcium phosphate (β -TCP) and calcium sulfate hemihydrate (α -form CSH) powders, that sets to a solid material at body temperature when mixed with a saline solution (injectable sodium chloride).

Bio 1-Quickset closely resembles the mineral phase of bone and gradually remodels to bone via osteoclastic resorption and osteoblastic new bone formation ^{(34) (35)}.

Methods

Injectability

For the purpose of injectability testings, the bone void filler was introduced in a commercial syringe (Plastipak, Becton Dickinson, Franklin Lake, New Jersey, USA) with a volume capacity of 20 ml, 24 mm of internal diameter and a nozzle diameter of 2.4 mm, and was extruded manually. The injectability was measured by comparing the amount of the substitute before and after extrusion from the syringe.



Figure 2: extrusion from the syringe

Injection time and setting time

The powder was mixed with saline solution during 30 seconds. The viscosity was then measured using a rotative viscosimeter (Tve-05s, Lamy Rheology, Champagne Au Mont d'Or, France) at 100 rpm, every thirty seconds during ten minutes.



Figure 3: Setting times measurements set-up

Compressive strength

Mechanical strength was evaluated in terms of compressive strength (CS) and measured in an Universal Testing Machine (LR30K, Lloyd instruments, Bognor Regis, West Sussex, UK) at a cross-head speed of 0.5 mm/min until fracture.

Six specimens were tested, sized 18.9 mm in diameter and 17.5 mm in height (height-to-diameter ratio almost equal to 1). The compressive strength (Pascal) is the force (Newton) applied to the cross section (m²).




Figure 4: Compression testing set-up

Results

Injectability

The injectability is defined as the relative amount of mixture which can be extruded from the syringe, according to the equation below (36):

$$INJ = \frac{(M_{before} - M_{syringe}) - (M_{after} - M_{syringe})}{M_{before} - M_{syringe}} \times 100$$

Where:

- INJ is the percentage of injectability,
- M_{before} is the weight of the syringe and the substitute before injecting,
- M_{after} is the weight of the syringe and the residual mixture after injecting,
- $M_{syringe}$ is the weight of the syringe.

Optimal β -TCP/CSH ratio achieves an injectability over 92%.

β -TCP/CSH ratio (%)	$M_{syringe}$ (g)	M_{before} (g)	M_{after} (g)	INJ (%)
47	14.29	22.31	14.66	95.4
50	14.25	24.08	14.99	92.5
50	14.17	23.97	14.45	97.1
55	14.23	25.06	18.11	64.2
55	14.08	27.78	17.07	78.2
60	14.23	26.36	21.50	40.1

Table 1: Injectability results

Injection time

Injection time is the delay after the powders and the liquid have been mixed and before the viscosity curve of the obtained paste show a deflexion.

The results obtained show that after 4 minutes the initial setting is too fast to allow injection. The mixture should be injected during the first three minutes after been mixed.




Figure 5: Injection time

The liquid-to-powder ratio (L/P) is the amount of liquid added to the powders. It plays a major role in the setting time. Excess liquid increases setting time.

Clinical experience has shown that high viscosity bone void fillers produce better clinical results, as compared to low viscosity bone void fillers ^{(37) (38)}.

Setting time

Setting time is the delay after the powders and the liquid have been mixed and before the mixture reach its maximal strength.

There are several factors influencing the setting and hardening of β -TCP based bone substitutes. Small particle size both accelerates the dissolution step, and thus the setting, and provides a stronger bone substitute ⁽³⁹⁾.

Other factors that accelerate the initial dissolution of β -TCP are acidic pH ⁽⁴⁰⁾, and increased temperature ^{(41) (42) (43) (44)}.




Figure 6: Setting time

Bio 1-Quickset achieves 94% of its maximal compressive strength 8 minutes after mixing.

Stability of the SBM Bio 1-Quickset performances was also evaluated by an accelerated ageing protocol:

- 1 year is equivalent to 6 weeks at 55°C
- 2 years is equivalent to 12 weeks at 55°C
- 5 years is equivalent to 28 weeks at 55°C

Delay (years)	Hardening time (min.'sec.'')
0	5'45'' (0'15'')
1	7'00'' (1'06'')
2	6'15'' (0'15'')
5	7'12'' (0'36'')

Table 2: Accelerated ageing setting time results

Compressive strength

The compressive strength is the applied force (MPa) at time where the first sign of crack appear on the sample (Figure 7).




Figure 7: Typical compression testing curve

The observed mean compressive strength is 1537 N, that is equivalent to a maximum stress of 6 MPa. These results showed that the Bio 1-Quickset injectable bone void filler has a compressive strength similar to cancellous bone ⁽⁴⁵⁾.




Figure 8: Mechanical characterization

Proportion of tricalcium phosphate

The compressive strength is directly correlated to the weight proportions of the powders. It was shown that the compressive strength could be controlled by varying the composition of the bone void filler. As the β -TCP content increases, the strength increases⁽⁴⁶⁾, but injectability decreases. Bio 1-Quickset β -TCP proportions have been determined for leading to an ideal compromise between injectability and compressive strength.

Temperature

The hydration reaction of β -TCP to CSH is temperature dependent and a higher compressive strength is obtained at 37 °C compared to room temperature (even if the final strength obtained at the end of the reaction is the same for both temperatures)⁽⁴²⁾.

Liquid-to-powder ratio

But the factor that affected the strength of the end product the most is liquid-to-powder ratio (L/P). The strength increased linearly with the decrease in added water⁽⁴⁶⁾. The SBM Bio 1-Quickset powder is mixed with a saline solution at a L/P ratio of 0.30 mL.g-1 (range 0.28 to 0.37 mL.g-1 depending on conditioning).

Discussion

Bio 1-Quickset associates two well known bone substitutes. It allows for having good injectability and ease of use, and to limit the drawback of too fast absorption of the bone void filler. The defined 30 to 60 seconds mixing and 2.30 minutes injection times, allows for a simple and ergonomic use of the system.

In vivo studies have shown that this bone void filler is bioactive, resorbable, and osteoconductive^{(34) (35)}. Thanks to our large background on β -TCP, mechanical strength characterization, surgical technique validation and according to the available scientific literature, we can conclude that Bio 1-Quickset injectable self hardening resorbable bone void filler is suitable for the filling of bone defects with no mechanical stress. It is indicated for the filling of bony voids or gaps that are not intrinsic to the stability of the bony structure, like cysts or benign tumors.

Bibliography

1. *Klinische Anforderungen an Knochenersatzstoffe.* **Niedhart C, Niethard FU.** Stuttgart : Enke Verlag, 1998, Bioceramics in orthopaedics— New applications, pp. S46–50.
2. *Biomechanical and histological evaluation of a calcium phosphate cement.* **Frankenburg EP, Goldstein SA, Bauer TW, Harris SA, Poser RD.** 8, Aug 1998, J. Bone Joint Surg., Vol. 80-A, pp. 1112-24.
3. *Applications of calcium phosphate-based cancellous bone void fillers in trauma surgery.* **Szpalski M, Gunzburg R.** 5 Suppl, 2002, Orthopedics, Vol. 25, pp. s601-9.
4. *Interporous hydroxyapatite as a bone graft substitute in tibial plateau fractures.* **Bucholz RW, Carlton A, Holmes R.** 1989, Clin Orthop Relat Res, Vol. 240, pp. 53-62.
5. *Biomechanical evaluation of fixation of intraarticular fractures of the distal part of the radius in cadaver: Kirschner wires compared with calcium-phosphate bone cement.* **Yetkinler DN, Ladd AL, Poser RD, Constantz BR, Carter D.** 3, 1999, J. Bone Joint Surg., Vol. 81-Br, pp. 391-399.
6. *Norian SRS cement compared with conventional fixation in distal radial fractures.* **Cassidy C, Jupiter J, Cohen M, Delli-Santi M, Fennell C, Leinberry C, Husband J, Ladd A, Seitz WR, Constanz B.** 11, 2003, J Bone Joint Surg, Vol. 85-A, pp. 2127-37.
7. *Treatment of fractures of the distal radius with a remodelable bone cement.* **Sanchez-Sotelo J, Munuera L, Madero R.** 6, 2000, J Bone Joint Surg., Vol. 82-B, pp. 856-63.
8. *Norian SRS versus external fixation in redisplaced distal radius fractures. A randomized study in 40 patients.* **Kopylov P, Runnqvist K, Jonsson K, Aspenberg P.** 1, 1999, Acta Orthop. Scand., Vol. 70, pp. 1-5.
9. *Clinical and radiological results of calcium phosphate cement-assisted balloon osteoplasty for Colles' fractures in osteoporotic senile female patients.* **Lida K, Sudo A, Ishiguro S.** 2, Mar 2010, J Orthop Sci., Vol. 15, pp. 204-9.
10. *Superior compressive strength of a calcaneal fracture construct augmented with remodelable cancellous bone cement.* **Thordarson DB, Hedman TP, Yetkinder DN.** 2, 1999, J. Bone Joint Surg., Vol. 81-Br, pp. 239-46.
11. *SRS cancellous bone cement augmentation of calcaneal fracture fixation.* **Thordarson DB, Bollinger M.** 5, 2005, Foot Ankle Int., Vol. 26, pp. 347-52.
12. *Open reduction and augmentation of internal fixation with an injectable skeletal cement for the treatment of complex calcaneal fractures.* **Schildhauer TA, Bauer TW, Josten C, Muhr G.** 5, 2000, J. Orthop. Trauma., Vol. 14, pp. 309-17.
13. *Primary clinical study on self-setting calcium phosphate cement in bone defect repair of extremities.* **Wang WB, Chen ZW, Chen TY, Wang Y, Zhao CD, Guang XD.** 2, Mar 2002, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, Vol. 16, pp. 100-2.
14. *Pathological fractures of the proximal humerus treated with a proximal humeral locking plate and bone cement.* **Siegel HJ, Lopez-Ben R, Mann JP, Ponce BA.** 5, May 2010, J. Bone Joint Surg. Br., Vol. 92, pp. 707-12.
15. *Minimal internal fixation and calcium-phosphate cement in the treatment of fractures of the tibial plateau.* **Keating JF, Hajducka CL, Harper J.** 1, 2003, J Bone Joint Surg., Vol. 85-B, pp. 68-73.
16. *Augmentation of tibial plateau fractures with calcium phosphate cement. A randomized study using radiostereometry.* **Larsson S, Berg P, Sagerfors M, Hollywood :** s.n., 2004, Trans. Ortop. Trauma. Soc. Annual meeting.
17. *Use of an injectable calcium phosphate bone cement in the treatment of tibial plateau fractures: a prospective study of twenty-six cases with twenty-month mean follow-up.* **Lobenhoffer P, Gerich T, Witte F, Tscherne H.** 3, 2002, J. Orthop. Trauma., Vol. 16, pp. 143-9.
18. *Norian SRS cement augmentation in hip fracture treatment. Laboratory and initial clinical results.* **Goodman SB, Bauer TW, Carter D, Casteleyn PP, Goldstein SA, Kyle RF, Larsson S, Stankewich CJ, Swiontkowski MF, Tencer AF, Yetkinler DN, Poser RD.** 1998, Clin Orthop, Vol. 348, pp. 42-50.
19. *Resorbable bone cement for augmentation of internally fixed hip fractures.* **Larsson S, Mattsson P, Bauer TW.** 3, 1999, Ann. Chir. Gyn., Vol. 88, pp. 205-13.
20. *Unstable trochanteric fractures augmented with calcium phosphate cement. A prospective randomized study using radiostereometry to measure fracture stability.* **Mattsson P, Larson S.** 2004, Scand. J. Surg., Vol. 93, pp. 223-8.
21. *Resorbable cement for augmentation of internally fixed unstable trochanteric fractures. A prospective randomized multicenter study.* **Mattsson P, Alberts A, Dahlbert G, Hyldahl HC, Sohlman M, Larsson S.** 9, 2005, J. Bone Joint Surg., Vol. 87, pp. 1203-9.
22. *Augmentation of femoral neck fracture fixation with an injectable calcium-phosphate bone mineral cement.* **Stankewich CJ, Swiontkowski MF, Tencer AF, Yetkinler DN, Poser RD.** 1996, J. Orthop. Res., Vol. 14, pp. 786-93.
23. *Augmentation of femoral neck fracture fixation with resorbable cement (Niran SRS) and its effect on early postoperative stability measured with RSA.* **Mattsson P, Larsson S.** 2003, Scand. J. Surg., Vol. 92, pp. 215-9.
24. *Treatment of intraosseous ganglia and bone cysts of the carpal bones with injectable calcium phosphate bone cement.* **Yajima H, Murata K, Kawamura K, Kawate K, Takakura Y.** 3, 2008, Hand Surg., Vol. 13, pp. 167-73.

25. *Preliminary clinical application of cancellous granule-type calcium phosphate cement.* **Abula A, Abaiyedula A, Yusufu A, Liu C, Huang H.** 9, Sep 2010, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, Vol. 24, pp. 1100-2.
26. *Clinical and histologic evaluation of calcium-phosphate bone cement in interproximal osseous defects in humans: a report in four patients.* **Mellonig JT, Valderrama P, Cochran DL.** 2, Apr 2010, Int J Periodontics Restorative Dent., Vol. 30, pp. 121-7.
27. *Calcium phosphate cement as a «barrier-graft» for the treatment of human periodontal intraosseous defects.* **Rajesh JB, Nandakumar K, Varma HK, Komath M.** 4, Oct-Dec 2009, Indian J. Dent. Res., Vol. 20, pp. 471-9.
28. *Comparison of injectable calcium phosphate bone cement grafting and open flap debridement in periodontal intrabony defects: a randomized clinical trial.* **Shirakata Y, Setoguchi T, Machigashira M, Matsuyama T, Furuichi Y, Hasegawa K, Yoshimoto T, Izumi Y.** 1, Jan 2008, J. Periodontol., Vol. 79, pp. 25-32.
29. *Development of a nonrigid, durable calcium phosphate cement for use in periodontal bone repair.* **Xu HH, Takagi S, Sun L, Hussain L, Chow LC, Guthrie WF, Yen JH.** 8, Aug 2006, J. Am. Dent. Assoc., Vol. 137, pp. 1131-8.
30. *Augmentation of femoral neck fracture fixation with an injectable calcium-phosphate bone mineral cement.* **Stankewich CJ, Swiontkowski MF, Tencer AF, Yetkinler DN, Poser RD.** 1996, J Orthop Res, Vol. 14, pp. 786-93.
31. *Use of injectable calcium phosphate cement for fracture fixation: a review.* **Larsson S, Bauer TW.** 2002, Clin Orthop, Vol. 395, pp. 23-32.
32. *Augmentation of pedicle screw fixation strength using an injectable calcium sulfate cement: an in vivo study.* **Yi X, Wang Y, Lu H, Li C, Zhu T.** 23, Nov 2008, Spine, Vol. 33, pp. 2503-9.
33. *Pedicle screw motion in the osteoporotic spine after augmentation with laminar hooks, sublaminar wires, or calcium phosphate cement: a comparative analysis.* **Tan JS, Kwon BK, Dvorak MF, Fisher CG, Oxland TR.** 16, Aug 2004, Spine, Vol. 29, pp. 1723-30.
34. *In vivo testing of a new in situ setting beta-tricalcium phosphate cement for osseous reconstruction.* **Niedhart C, Maus U, Redmann E, Siebert CH.** 4, June 2001, J Biomed Mater Res., Vol. 55, pp. 530-7.
35. *Evaluation of a resorbable, in situ setting bone substitute in a sheep model.* **Niedhart C, Maus U, Piroth W, Miltner O, Schmidt-Rohlfing B, Siebert CH.** 1, Oct 2004, J Biomed Mater Res B Appl Biomater., Vol. 71, pp. 123-9.
36. *Injectability evaluation of tricalcium phosphate bone cement.* **Alves HL, Dos Santos LA, Bergmann CP.** 5, May 2008, J Mater Sci Mater Med., Vol. 19, pp. 2241-6.
37. *Prognosis of total hip replacement in Sweden. Follow-up of 92,675 operations performed 1978-1990.* **Malchau H, Herberts P, Ahnfelt L.** 5, Oct 1993, Acta Orthop. Scand., Vol. 64, pp. 497-506.
38. *The Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties.* **Havelin LI, Engesaeter LB, Espehaug B, Furnes O, Lie SA, Vollset SA.** 4, Aug 2000, Acta Orthop. Scand., Vol. 71, pp. 337-53.
39. *Influence of the particle size of the powder phase in the setting and hardening behaviour of a calcium phosphate cement.* **Ginebra MP, Fernández E, Driessens FCM, Boltong MG, Planell JA.** Paris : Elsevier Science, 1997, Bioceramics , Vol. 10, pp. 481-4.
40. *Reactivity of α -tricalcium phosphate.* **Durucan C, Brown PW.** 2002, J Mater Sci, Vol. 37, pp. 963-9.
41. *Calculation of the solubility diagrams in the system $Ca(OH)_2-H_3PO_4-KOH-HNO_3-CO_2-H_2O$.* **Vereecke G, Lemaitre J.** 1990, J Cryst Growth, Vol. 104, pp. 820-32.
42. *The effects of temperature on the behaviour of an apatitic calcium phosphate cement.* **Ginebra MP, Fernández E, Driessens FCM, Boltong MG, Muntasell J, Font J, Planell JA.** b, 1995, J Mater Sci Mat Med, Vol. 6, pp. 857-60.
43. *Effect of temperature and immersion on the setting of some calcium phosphate cements.* **Driessens FCM, Boltong MG, De Maeyer EAP, Verbeeck RMH, Wenz R.** 2000, J Mater Sci Mat Med, Vol. 11, pp. 453-7.
44. *α -Tricalcium phosphate hydrolysis to hydroxyapatite at and near physiological temperature.* **Durucan C, Brown PW.** 2000, J Mater Sci Mat Med, Vol. 11, pp. 365-71.
45. *Tensile fracture of cancellous bone.* **Carter DR, Schwab GH, Spengler DM.** 5, Oct 1980, Acta Orthop Scand., Vol. 51, pp. 733-41.
46. *Characterization of a novel calcium phosphate/sulphate bone cement.* **Nilsson M, Fernández E, Sarda S, Lidgren L, Planell JA.** 2002, Journal of Biomedical Materials Research, Vol. 61, pp. 600-607.



SBM SAS



Read carefully the instructions for use that comes with the medical device or labeling provided to medical professionals. Class III device.
Document not legally binding - Can be modified without prior notice.
Manufactured by SBM © 2013. Ref: MGTRAFFEN - v2.0113

ZI du Monge
65100 LOURDES
FRANCE
Phone: (+33) 5 62 42 32 12
Fax: (+33) 5 62 42 32 52
www.s-b-m.fr